🇺🇸 FDA
Pipeline program

EP0062, ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets

EP0062-101

Phase 2 small_molecule active

Quick answer

EP0062, ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets for Breast Cancer is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Lacuna Pharma Pty Ltd
Indication
Breast Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials